Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.

Ulrich M, Lange-Asschenfeldt S, Skak K, Skov T, Østerdal ML, Röwert-Huber HJ, Zibert JR, Stockfleth E.

J Drugs Dermatol. 2016 Oct 1;15(10):1181-1189.

PMID:
27741334
2.

Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice.

Erlendsson AM, Thaysen-Petersen D, Bay C, Hald A, Skak K, Zibert JR, Paasch U, Wulf HC, Haedersdal M.

PLoS One. 2016 Sep 16;11(9):e0162597. doi: 10.1371/journal.pone.0162597. eCollection 2016.

3.

Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers.

Bertelsen M, Stahlhut M, Grue-Sørensen G, Liang X, Christensen GB, Skak K, Engell KM, Högberg T.

Dermatol Ther (Heidelb). 2016 Dec;6(4):599-626. Epub 2016 Aug 8.

4.

IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.

Le TT, Skak K, Schroder K, Schroder WA, Boyle GM, Pierce CJ, Suhrbier A.

PLoS One. 2016 Apr 21;11(4):e0153975. doi: 10.1371/journal.pone.0153975. eCollection 2016.

5.

Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis.

Martel BC, Litman T, Hald A, Norsgaard H, Lovato P, Dyring-Andersen B, Skov L, Thestrup-Pedersen K, Skov S, Skak K, Poulsen LK.

Exp Dermatol. 2016 Jun;25(6):453-9. doi: 10.1111/exd.12967. Epub 2016 Feb 26.

PMID:
26841714
6.

Different cytokine profiles of skin-derived T cell cultures from patients with atopic dermatitis and psoriasis.

Martel BC, Dyring-Andersen B, Skov L, Thestrup-Pedersen K, Skov S, Skak K, Poulsen LK.

Inflamm Res. 2016 Apr;65(4):265-72. doi: 10.1007/s00011-015-0912-z. Epub 2015 Dec 31.

PMID:
26722669
7.

Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.

Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF.

Mol Cancer Ther. 2015 Sep;14(9):2132-42. doi: 10.1158/1535-7163.MCT-15-0023-T. Epub 2015 Jun 26.

8.

Human Atopic Dermatitis Skin-derived T Cells can Induce a Reaction in Mouse Keratinocytes in vivo.

Martel BC, Blom L, Dyring-Andersen B, Skov L, Thestrup-Pedersen K, Skov S, Skak K, Poulsen LK.

Scand J Immunol. 2015 Aug;82(2):125-34. doi: 10.1111/sji.12316.

9.

Objective Quantification of Immune Cell Infiltrates and Epidermal Proliferation in Psoriatic Skin: A Comparison of Digital Image Analysis and Manual Counting.

Soendergaard C, Nielsen OH, Skak K, Røpke MA, Seidelin JB, Kvist PH.

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):453-8. doi: 10.1097/PAI.0000000000000191.

PMID:
25906125
10.

[Tolerance and safety of drug arglabin].

Tabriz NS, Skak KS, Mytaikhan ZhM, Kozhamuratov MT, Serikbaev NM.

Georgian Med News. 2014 Dec;(237):70-6. Russian.

PMID:
25617105
11.

IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma.

Coquet JM, Skak K, Davis ID, Smyth MJ, Godfrey DI.

Clin Transl Immunology. 2013 Oct 18;2(10):e6. doi: 10.1038/cti.2013.7. eCollection 2013 Oct.

12.

Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K.

J Immunother. 2010 Apr;33(3):236-49. doi: 10.1097/CJI.0b013e3181c0c1cb.

PMID:
20445344
13.

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.

Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ.

J Immunol. 2009 Dec 1;183(11):7326-36. doi: 10.4049/jimmunol.0902697. Epub 2009 Nov 13.

14.

IL-21: roles in immunopathology and cancer therapy.

Søndergaard H, Skak K.

Tissue Antigens. 2009 Dec;74(6):467-79. doi: 10.1111/j.1399-0039.2009.01382.x. Epub 2009 Oct 21. Review.

PMID:
19845910
15.

In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.

Skak K, Søndergaard H, Frederiksen KS, Ehrnrooth E.

Cytokine. 2009 Dec;48(3):231-8. doi: 10.1016/j.cyto.2009.07.039. Epub 2009 Aug 25.

PMID:
19709902
16.

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G.

Clin Cancer Res. 2009 Mar 15;15(6):2123-9. doi: 10.1158/1078-0432.CCR-08-2663. Epub 2009 Mar 10.

17.

The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.

Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA, Odum N.

Mol Immunol. 2009 Feb;46(5):812-20. doi: 10.1016/j.molimm.2008.09.006. Epub 2008 Oct 22.

PMID:
18947877
18.

Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.

Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD.

Cancer Immunol Immunother. 2009 Jun;58(6):843-54. doi: 10.1007/s00262-008-0600-8. Epub 2008 Oct 17.

PMID:
18925392
19.

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.

Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K.

Cancer Immunol Immunother. 2008 Oct;57(10):1439-49. doi: 10.1007/s00262-008-0479-4. Epub 2008 Feb 20.

20.

Interleukin 21: combination strategies for cancer therapy.

Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV.

Nat Rev Drug Discov. 2008 Mar;7(3):231-40. doi: 10.1038/nrd2482. Review. Erratum in: Nat Rev Drug Discov. 2008 Mar;7(3):272.

PMID:
18259184
21.

Interleukin-21 signaling: functions in cancer and autoimmunity.

Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV.

Clin Cancer Res. 2007 Dec 1;13(23):6926-32. Review.

22.

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression.

Skak K, Frederiksen KS, Lundsgaard D.

Immunology. 2008 Apr;123(4):575-83. Epub 2007 Nov 14.

23.

IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes.

Barker BR, Parvani JG, Meyer D, Hey AS, Skak K, Letvin NL.

J Immunol. 2007 Sep 15;179(6):3596-603.

24.

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA.

Clin Cancer Res. 2007 Jun 15;13(12):3630-6.

25.

Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice.

Martinic MM, Juedes AE, Bresson D, Homann D, Skak K, Huber C, Ling E, Ejrnaes M, Wolfe T, Togher L, Christen U, von Herrath MG.

Diabetes. 2007 Apr;56(4):1059-68.

26.

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.

Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M.

Cancer Immunol Immunother. 2007 Sep;56(9):1417-28. Epub 2007 Feb 7.

PMID:
17285290
27.

Preservation of beta-cell function during immune-mediated, B7-1-dependent alpha-cell destruction.

Skak K, Haase C, Michelsen BK.

Eur J Immunol. 2005 Sep;35(9):2583-90.

29.

Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.

Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H.

Diabetes. 2004 Apr;53(4):1089-95.

30.

TNF-alpha impairs peripheral tolerance towards beta-cells, and local costimulation by B7.1 enhances the effector function of diabetogenic T cells.

Skak K, Guerder S, Picarella DE, Brenden N, Flavell RA, Michelsen BK.

Eur J Immunol. 2003 May;33(5):1341-50.

31.

Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression.

Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, Ødum N.

Blood. 2003 Feb 15;101(4):1430-8. Epub 2002 Oct 17.

32.

PDX-1 mediates glucose responsiveness of GAD(67), but not GAD(65), gene transcription in islets of Langerhans.

Pedersen AA, Petersen HV, Videbaek N, Skak K, Michelsen BK.

Biochem Biophys Res Commun. 2002 Jul 12;295(2):243-8.

PMID:
12150938
33.

Characterization of the rat GAD67 gene promoter reveals elements important for basal transcription and glucose responsiveness.

Pedersen AA, Videbaek N, Skak K, Petersen HV, Michelsen BK.

DNA Seq. 2001;11(6):485-99.

PMID:
11696975
34.

Supplemental Content

Support Center